Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 13/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.38 |
| ▸ | CTSD | P07339 | 4/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.35 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.35 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.35 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2153402 | 0.87 | BACE1 (0.39) | MEN1KMT2ABRD4BACE1BACE2 | |
| SCHEMBL7558483 | 0.77 | BACE1 (0.40) | BACE1BACE2CTSDAKR1B1ALDH1A1 | |
| SCHEMBL7517439 | 0.76 | KMT2A (0.44) | MEN1KMT2ABRD4BACE1CTSD | |
| SCHEMBL14856024 | 0.75 | BACE1 (0.40) | BACE1BACE2CTSDAKR1B1 | |
| SCHEMBL2154201 | 0.74 | BACE1 (0.46) | BACE1BACE2CTSD | |
| SCHEMBL10081942 | 0.74 | BACE1 (0.34) | BACE1BACE2CTSD | |
| SCHEMBL1173343 | 0.72 | AKR1B1 (0.50) | BACE1BACE2CTSDAKR1B1 | |
| SCHEMBL1173345 | 0.72 | AKR1B1 (0.50) | BACE1BACE2CTSDAKR1B1 | |
| SCHEMBL252703 | 0.71 | MEN1 (0.37) | MEN1KMT2ABRD4BACE1BACE2 | |
| SCHEMBL15027687 | 0.71 | BACE1 (0.37) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150322038-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | disclosed |
| EP-2663308-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | Novartis AG (CH) | 2013-11-20 | — | — | EP | disclosed |
| EP-2519515-B1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2013-11-06 | — | — | EP | disclosed |
| EP-2519515-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-11-07 | — | — | EP | disclosed |
| US-20120277244-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-11-01 | — | — | US | disclosed |
| WO-2012095521-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2012-07-19 | — | — | WO | disclosed |
| WO-2011080176-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | MEN1 1871/4885KMT2A 2117/4885BRD4 617/4885 |
| US-20150322038-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIK5, GRIN2C, GRIN2A | MEN1 1912/4885KMT2A 1578/4885BRD4 1421/4885 |
| US-20120277244-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIK5, GRIN2C, GRIN2A | MEN1 1811/4885KMT2A 1680/4885BRD4 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.